T reatment A ction G roup Update on Global TB Research By Claire Wingfield Treatment Action Group Advisory Council for the Elimination of Tuberculosis.

Slides:



Advertisements
Similar presentations
1 The role of NEPAD in improving quality and effectiveness of aid for Agricultural development Amadou Allahoury Diallo Senior Water Specialist NEPAD.
Advertisements

WHO Expert Working Group on R&D and Financing January 2009 G-FINDER: Global Funding of Innovation for Neglected Diseases.
Global Alliance for Vaccines and Immunization. n An Alliance u Traditional and new partners u Public and private sector n Partners have in common: u Situation.
The Effectiveness of Global Health Partnerships Findings and Lessons from a World Bank Evaluation of Global Health Programs Uma Lele April 14, 2005.
Pharmaceuticals and Global Health Inequalities and Innovation in the 21 st Century.
TBD-UK: The UK response in the discovery and development of new TB drugs. Dr Geoff Coxon Deputy Leader & Director of Medicinal Chemistry, TBD-UK APPG-TB.
Bill & Melinda Gates Foundation Male Circumcision funding Heather Harrison WHO meeting June, 2010.
Dr. E. Anne Peterson, MD, MPH Assistant Administrator, Bureau for Global Health, USAID Sustainable Investment and Donor Coordination Stop TB Partners Forum.
Overview of the Global Fund: Guiding Principles Grant Cycle / Processes & Role of Public Private Partnerships Johannesburg, South Africa Tatjana Peterson,
Christine Lubinski Vice President for Global Health Infectious Diseases Society of America April 17, 2009 Germs Go Global Tuberculosis and HIV/TB Co-Infection.
GLOBAL HEALTH R&D FINANCING: THE EXPERIENCE OF NON-PROFIT PRODUCT DEVELOPMENT ORGANIZATIONS Claire Wingfield November 1, 2013 The economic urgency and.
HIV Prevention Research & Development Investment in 2013 In a changing global development, economic, and human rights landscape Presented at the International.
Working Together to Improve Global Health
Mexico International AIDS Conference Global Architecture of HIV/AIDS Financing Remarks by Joy Phumaphi, Vice President of the World Bank’s Human Development.
Public Sector Donors Who Increased Funding for HIV Vaccine R&D in 2011 How much did donor funding increase?
TB/HIV: Impact and Opportunities Helene Gayle, MD, MPH Bill and Melinda Gates Foundation DATE, 2004.
COMPANION GRAPHS. Annual Global Plan Research Funding Targets vs Investments $800,000,000 $600,000,000 $400,000,000 $200,000,000 $0 Fundamental.
Technical Advisory Group meeting, WHO/WPRO
BIOTECHNOLOGY COMPANIES AND INFECTIOUS DISEASE Devon Sherwood, Michael Deganich, Tyler Fulton.
The Global Fund to Fight AIDS, Tuberculosis and Malaria: Results and Innovation in Development Cooperation for Health Silvia Ferazzi Manager, Donor Governments.
22 March 2012 Europe and ACP together against tuberculosis European Parliament, Rue Wiertz 60 BRUSSELS Charles S Mgone EDCTP Executive Director.
PUTTING AN END TO TB WHERE ARE THE OPPORTUNITIES AND WHAT ARE THE CHALLENGES? STRATEGY MEETING ON RESOURCE MOBILIZATION FOR THE GLOBAL FUND TO FIGHT AIDS,
Teresa Guthrie M.PH (Health Economics) HIV modelling for in-country ownership solutions – generation of evidence IAS Conference, Washington DC, July.
The Value of Partnerships in Fighting HIV/AIDS in Romania: Bringing Children New Hope Jeffrey L. Sturchio Vice President, External Affairs Europe, Middle.
Civil Society in Decision Making for Immunization Policies: the example of National Immunization Technical Advisory Groups (NITAGs) Center for Vaccine.
DRUG-RESISTANT TB in SOUTH AFRICA: Issues & Response _ ______ _____ _ ______ _____ ___ __ __ __ __ __ _______ ___ ________ ___ _______ _________ __ _____.
HIV NON-INTERVENTION: A COSTLY OPTION A NEW FRAMEWORK FOR GLOBALIZATION Jeffrey D. Sachs, PhD Director, Center for International Development Galen L. Stone.
Tajikistan The Global Fund to Fight AIDS, Tuberculosis and Malaria Support to the Strategic Plan to Prevent HIV/AIDS Epidemics in Tajikistan. November.
COUNTRY ACTION: SUSTAINABLE INVESTMENT STOP TB PARTNERSHIP FORUM STOP TB PARTNERSHIP FORUM 24TH-26TH MARCH TH-26TH MARCH 2004 BY BY MRS NENADI USMAN.
2005–2012 NIH Funding for Select Infectious Diseases (in Millions) * Includes ARRA stimulus funds National Institutes of Health (U.S.). Estimates of funding.
WHO Expert Working Group on R&D Financing Stop TB New Tools Working Groups Marcos Espinal Executive Secretary.
MALARIA AND NEGLECTED TROPICAL DISEASES (NTDs): FINDINGS FROM THE 2012 G-FINDER REPORT.
A new start for the Lisbon Strategy Knowledge and innovation for growth.
The U.S. President’s Emergency Plan for AIDS Relief (PEPFAR) “The Role of PEPFAR in the Caribbean Region” William Conn, PEPFAR Coordinator PANCAP 15 th.
Funding Universal Access through a “Global Health Charge” on alcohol and tobacco: feasibility in the 20 countries with the largest HIV epidemics Dr Andrew.
1 FIND and Operational Research in HIV-Associated Tuberculosis Rick O’Brien Foundation for Innovative New Diagnostics, Geneva.
African Business Leaders on Health: GBC Conference on TB, HIV-TB Co-infection & Global Fund Partnership Johannesburg, October 11, 2010 The state of Global.
OCTOBER 2014 TREATMENT ACTION GROUP MIKE FRICK. Annual Global Plan Research Funding Targets versus 2013 Funding $600,000,000 $800,000,000 $400,000,000.
Update of the Global Plan to Stop TB TB/HIV Working Group Meeting Geneva, November 2009 Christian Lienhardt.
The AIDS Vaccine Policy Agenda Holly J. Wong Vice President, Public Policy International AIDS Vaccine Initiative (IAVI) Vienna, Austria International AIDS.
1 DEWG meeting October 2009 Human Resource Development for TB Control (HRD-TB) Sub Group within the DEWG of the Stop TB Partnership. Wanda Walton.
Meeting of the Working Group on TB Drug Development Why you need to be engaged? Marcos Espinal Executive Secretary Stop TB Partnership 29 October 2004.
Vaccine Enterprise & Collaboration Bill Snow, Director 19 January 2013 CHVI Afri-Can Forum.
ASTMH 2015 Capitol Hill Day Asks. ASTMH “Asks” Provide robust funding for NIH, CDC, USAID and DoD global health and infectious disease programs for fiscal.
Tracking the Shortfall in TB Research Funding Javid Syed Treatment Action Group (TAG)
World Vision Experiences in Making ART Treatment Affordable and Available Dr. Daniel J Malleboyina M.B.B.S, MBA, MPH Regional Advisor HIV & AIDS- Asia.
The Bank’s Regional HIV/AIDS Strategies An Overview.
A global partnership to stop measles & rubella 1 Measles & Rubella Initiative --Who We Are-- Stephen Cochi, MD, MPH Global Immunization Division Centers.
Malaria a story of ELIMINATION A partnership of:.
International Aid Towards HIV/AIDs in sub-Saharan Africa Ally H. Van Valen.
Compendium of Indicators for Monitoring and Evaluating National Tuberculosis Programs.
STRENGTHENING THE CAPACITY OF KEY POPULATIONS TO ENGAGE IN NATIONAL FUNDING PLATFORMS AND PROCESSES - TANZANIA CONTEXT ARASA PARTNERS FORUM 2015 PRESENTER;
TB R&D goals of the WHO Ministerial Conference 2017 and HLM on TB at UNGA 2018 Dr Mario RAVIGLIONE Director GTB, WHO TAG/ACTION Webinars 30 May 2017.
The HIV Response Where are we now?
Funding for TB Research
State of the TB Alliance
Maintaining Visibility 2009
tracking microbicide funding
Donor Government Disbursements for HIV,
FRAMEWORK FOR RESOURCE MOBILIZATION
Common Messaging Platform
  FOR HIV PREVENTION RESEARCH & DEVELOPMENT RESOURCE TRACKING
Disease Control Priorities Project Overview
Jeffrey D. Sachs, PhD Director, Center for International Development
TB/HIV Working Group: Achievements
Objectives of Session Provide an overview of the development of Compendium Explain the organization of the Compendium and how indicators are used Provide.
Global Health Technology
Financing South Africa’s HIV Response
Paul Stoffels, MD Vice Chairman, Chief Scientific Officer, Johnson & Johnson.
HIV Funding from Donor Governments,
Presentation transcript:

T reatment A ction G roup Update on Global TB Research By Claire Wingfield Treatment Action Group Advisory Council for the Elimination of Tuberculosis Centers for Disease Control and Prevention (CDC) March 20-21, 2007 Atlanta, Georgia

Who is TAG? Treatment Action Group (TAG) was founded in January, 1992, and is the first and only AIDS organization dedicated solely to advocating for larger and more efficient research efforts, both public and private, towards finding a cure for AIDS. The TB/HIV Project works to combat TB/HIV co- infection through a combination of community-based advocacy, education and mobilization efforts involving AIDS advocates in developed and developing countries. The TB/HIV Project is supported by a grant from the Bill & Melinda Gates Foundation. T reatment A ction G roup

TB Research The 1940’s and 50’s were the heyday of TB drug discovery. Between the 1940’s and 1980 there was dramatic decline in global TB disease, and as a result there was a stall in TB R&D. But TB made a dramatic comeback with the dawn of the HIV pandemic. T reatment A ction G roup

T reatment A ction G roup

Methodology Objective was to highlight gaps in spending as well as in areas of scientific study in TB R&D. Funding data were collected largely from original-source donors. Data were collected from public and private sector sources and were supplemented by interviews. Most of the data is based on self-reporting by recipients and representatives of funding sources. T reatment A ction G roup

1NIAID / NIH 2Gates Foundation 3Medical Research Council (UK) 4Other Institutes & Centers / NIH 5Centers for Disease Control 6Company X 7Wellcome Trust 8NHLBI / NIH 9European Commission 6th Framework 10Otsuka TOP 10 Donors to TB Research (2005) Who Are the Funders? T reatment A ction G roup Feuer C. Tuberculosis Research & Development: A Critical Analysis. Treatment Action Group (TAG); 2006

T reatment A ction G roup Feuer C. Tuberculosis Research & Development: A Critical Analysis. Treatment Action Group (TAG); 2006 Overall TB R&D Investment (2005 = $392.7M)

T reatment A ction G roup ? ?? Feuer C. Tuberculosis Research & Development: A Critical Analysis. Treatment Action Group (TAG); 2006 Investment in TB Research Actual vs. Need (2005)

T reatment A ction G roup 2005 Spending

T reatment A ction G roup 2005 Spending

T reatment A ction G roup 2005 Spending

T reatment A ction G roup 2005 Spending

T reatment A ction G roup 2005 Spending

T reatment A ction G roup

T reatment A ction G roup

T reatment A ction G roup

T reatment A ction G roup

T reatment A ction G roup 2005 Spending

FY05 GP 2006 base 5-foldGP2TAG 10 yr Actualestimateincrease2015rec By new tool category TB diagnostics TB drugs TB vaccines New tools sub Basic research Applied/Infrastructure Operational research Subtotal Total TB R&D How Much TB R&D Funding is Really Needed (Dollars in Millions) T reatment A ction G roup Why are the Global Plan Numbers Insufficient?

Action Points A comprehensive global TB R&D agenda is urgently needed. TB R&D needs better global/national coordination. Industry needs to be more transparent about TB R&D investments. Reporting consistency is needed to better track and annually update TB R&D. Need greater involvement from all funders in TB R&D. Emerging countries such as Brazil, China, India, Russia, South Africa and Thailand should play a bigger role. A five-fold (400%) increase in annual TB R&D expenditures is the minimum necessary to achieve the goals set out in The Global Plan II. T reatment A ction G roup

THANKS Javid Syed, TAG Mark Harrington, TAG Eric Goemaere, MSF